What is the overall financial health of Johnson & Johnson as indicated by this filing?

This filing provides a snapshot of JNJ's financial health for the first quarter of fiscal year 2010. Investors should review the Consolidated Balance Sheets for assets, liabilities, and equity, the Statements of Earnings for profitability, and the Statements of Cash Flows for cash generation and usage to assess the company's financial stability and operational performance during this period.

What were the main drivers of JNJ's performance in the first quarter of 2010?

The Management's Discussion and Analysis (MD&A) section is the primary source for understanding the drivers of JNJ's performance. It typically breaks down results by segment (e.g., Pharmaceuticals, Medical Devices, Consumer Health) and discusses factors such as sales growth, product launches, competitive pressures, and operational efficiencies.

Are there any significant legal or regulatory issues that investors should be aware of?

Item 1 of Part II, 'Legal Proceedings,' would detail any significant ongoing litigation or regulatory matters that could have a material impact on the company's financial condition or results of operations. Investors should carefully review this section for potential liabilities or risks.

How is JNJ managing its market risks?

Item 3, 'Quantitative and Qualitative Disclosures About Market Risk,' provides information on JNJ's exposure to various market risks, such as interest rate risk, foreign currency exchange rate risk, and equity price risk, and the strategies employed to manage these risks. This is important for understanding potential impacts on earnings and cash flows.

JNJ 10-Q Quarterly Report Q2 FY2010 — Revenue, Net Income, EPS

Summary

Johnson & Johnson's (JNJ) 10-Q filing for the first quarter of fiscal year 2010, ending April 3, 2010, reveals a company navigating a period of stable performance with ongoing strategic management. The report details the company's financial position, results of operations, and cash flows, providing investors with insight into the operational health of this diversified healthcare giant. Key areas of focus for investors would include the revenue generation across its various segments and the company's ability to manage its costs and cash generation effectively.

Financial Highlights

51 data points

Beta

Revenue

$15.63B

0.7% Gross Margin

Net Income

$4.53B

0.3% Net Margin

EPS (Diluted)

$1.62

Total Assets

$93.44B

Cash & Equivalents

$13.74B

Free Cash Flow

$3.29B

Financial Statements

Beta

Revenue	$15.63B
Cost of Revenue	$4.53B
Gross Profit	$11.10B
SG&A Expenses	$4.78B
Interest Expense	$108.00M
Net Income	$4.53B
EPS (Basic)	$1.64
EPS (Diluted)	$1.62
Shares Outstanding (Basic)	2.76B
Shares Outstanding (Diluted)	2.80B

Key Highlights

1The report presents unaudited financial statements for the first fiscal quarter ended April 4, 2010, compared to the same period in the prior year, offering a view of recent performance trends.
2Key financial statements provided include Consolidated Balance Sheets, Statements of Earnings, and Statements of Cash Flows, essential for understanding the company's financial health and liquidity.
3Management's Discussion and Analysis (MD&A) section offers qualitative insights into the company's financial condition and results of operations, crucial for understanding the drivers behind the reported numbers.
4The filing includes quantitative and qualitative disclosures about market risk, giving investors an understanding of how JNJ manages potential financial exposures.
5Information on Legal Proceedings and Unregistered Sales of Equity Securities is also included, addressing potential contingent liabilities and capital structure changes.
6The report covers the period immediately following the 2008-2009 financial crisis, offering a perspective on JNJ's performance in the initial stages of economic recovery.

JOHNSON & JOHNSON Quarterly Report for Q2 Ended Apr 4, 2010

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions